	US 11,939,633 B2
	COTL1 protein involved in maintaining homeostasis of hematopoietic stem cell, and use thereof
Seon-Yong Jeong, Yongin-si (KR); Eunkuk Park, Suwon-si (KR); and Gijeong Kim, Suwon-si (KR)
Assigned to AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Suwon-si (KR)
Appl. No. 16/612,031
Filed by AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Suwon-si (KR)
PCT Filed May 10, 2018, PCT No. PCT/KR2018/005343 § 371(c)(1), (2) Date Nov. 8, 2019, PCT Pub. No. WO2018/212503, PCT Pub. Date Nov. 22, 2018.
Claims priority of application No. 10-2017-0062323 (KR), filed on May 19, 2017.
Prior Publication US 2020/0165674 A1, May 28, 2020
Int. Cl. C12N 15/113 (2010.01); C12Q 1/6883 (2018.01); G01N 33/68 (2006.01)

CPC C12Q 1/6883 (2013.01) [C12N 15/113 (2013.01); G01N 33/6893 (2013.01); C12N 2310/14 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/4703 (2013.01); G01N 2500/00 (2013.01); G01N 2800/22 (2013.01)]

3 Claims

1. A method for treating a blood-related disease in a subject in need thereof, the method comprising administering to the subject an effective amount of an inhibitor of expression of COTL1 protein,

wherein the blood-related disease is a leukemia caused by an increase in abnormal proliferation of hematopoietic stem cells, and the treating comprises a decrease in a number of hematopoietic stem cells compared to prior to the administering,

wherein the administering reduces a number of hematopoietic stem cells, and

wherein the inhibitor is any one selected from the group consisting of an antisense nucleotide, a small interfering RNA (siRNA), and a short hairpin RNA (shRNA), which each bind complementarily to the mRNA of the COTL1 gene, and a combination thereof,

wherein the inhibitor is a morpholino oligonucleotide comprising the sequence of SEQ ID: 5.